SINOPHARM GROUP 1/5/O.N. Total Liabilities
SINOPHARM GROUP 1/5/O.N. total liabilities. Based on the latest financial reports, SINOPHARM GROUP 1/5/O.N. (X2S1) has total liabilities worth €256.20 Billion EUR (≈ $299.53 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SINOPHARM GROUP 1/5/O.N. (X2S1) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SINOPHARM GROUP 1/5/O.N. (2021–2025)
Total liabilities of SINOPHARM GROUP 1/5/O.N. from 2021 to 2025. This chart illustrates how SINOPHARM GROUP 1/5/O.N.'s total liabilities have evolved over time, based on quarterly financial data.
SINOPHARM GROUP 1/5/O.N. Competitors by Total Liabilities
The table below lists competitors of SINOPHARM GROUP 1/5/O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SmartCentres Real Estate Investment Trust
TO:SRU-UN
|
Canada | CA$5.79 Billion |
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
USA | $214.90 Million |
|
Now Inc
NYSE:DNOW
|
USA | $1.72 Billion |
|
Bright Horizons Family Solutions Inc
NYSE:BFAM
|
USA | $2.85 Billion |
|
Hybio Pharmaceutical
SHE:300199
|
China | CN¥2.50 Billion |
|
Rising Nonferrous Metals Share Co Ltd
SHG:600259
|
China | CN¥4.19 Billion |
|
Fuchs Petrolub SE
XETRA:FPE
|
Germany | €983.00 Million |
|
EXOSENS PROM
PA:EXENS
|
France | €444.20 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down SINOPHARM GROUP 1/5/O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SINOPHARM GROUP 1/5/O.N. total assets.
Liquidity & Leverage Metrics
SINOPHARM GROUP 1/5/O.N. Total Liabilities Ratios Explained
SINOPHARM GROUP 1/5/O.N. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SINOPHARM GROUP 1/5/O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SINOPHARM GROUP 1/5/O.N. (2021–2025)
The table below shows the annual total liabilities of SINOPHARM GROUP 1/5/O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €256.20 Billion ≈ $299.53 Billion |
-3.74% |
| 2024-12-31 | €266.14 Billion ≈ $311.15 Billion |
+1.17% |
| 2023-12-31 | €263.08 Billion ≈ $307.56 Billion |
+3.29% |
| 2022-12-31 | €254.71 Billion ≈ $297.78 Billion |
+8.04% |
| 2021-12-31 | €235.76 Billion ≈ $275.63 Billion |
-- |
About SINOPHARM GROUP 1/5/O.N.
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more